Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles

References

• Oguma K, Syuto B, Iida H, Kubo S. Antigenic similarity of toxins produced by Clostridium botulinum type C and D strains. Infect Immun 1980; 30:656-60; PMID:6785231
   PubMed Web of Science ®Google Scholar
• Barash JR, Arnon SS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 2014; 209:183-91; PMID:24106296; http://dx.doi.org/10.1093/infdis/jit449
   PubMed Web of Science ®Google Scholar
• Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001; 285:1059-70; PMID:11209178; http://dx.doi.org/10.1001/jama.285.8.1059
   PubMed Web of Science ®Google Scholar
• Chen S, Xu Q, Zeng M. Oral vaccination with an adenovirus-vectored vaccine protects against botulism. Vaccine 2013; 31:1009-11; PMID:23295065; http://dx.doi.org/10.1016/j.vaccine.2012.12.054
   PubMed Web of Science ®Google Scholar
• CDC. Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. Morb Mortal Wkly Rep (MMWR) 2011; 60:1454-5
   PubMedGoogle Scholar
• Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie 2000; 82:955-66; PMID:11086225; http://dx.doi.org/10.1016/S0300-9084(00)01173-1
   PubMed Web of Science ®Google Scholar
• Webb RP, Smith LA. What next for botulism vaccine development? Expert Rev Vaccines 2013; 12:481-92; PMID:23659297; http://dx.doi.org/10.1586/erv.13.37
   PubMed Web of Science ®Google Scholar
• Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 1998; 66:4817-22; PMID:9746584
   PubMed Web of Science ®Google Scholar
• Clayton J, Middlebrook JL. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine 2000; 18:1855-62; PMID:10699334; http://dx.doi.org/10.1016/S0264-410X(99)00253-4
   PubMed Web of Science ®Google Scholar
• Bennett AM, Perkins SD, Holley JL. DNA vaccination protects against botulinum neurotoxin type F. Vaccine 2003; 21:3110-7; PMID:12804837; http://dx.doi.org/10.1016/S0264-410X(03)00260-3
   PubMed Web of Science ®Google Scholar
• Jathoul AP, Holley JL, Garmory HS. Efficacy of DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters. Vaccine 2004; 22:3942-6; PMID:15364442; http://dx.doi.org/10.1016/j.vaccine.2004.04.006
   PubMed Web of Science ®Google Scholar
• Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997; 239:389-401; PMID:9434729; http://dx.doi.org/10.1006/viro.1997.8878
   PubMed Web of Science ®Google Scholar
• Lee JS, Pushko P, Parker MD, Dertzbaugh MT, Smith LA, Smith JF. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun 2001; 69:5709-15; PMID:11500447; http://dx.doi.org/10.1128/IAI.69.9.5709-5715.2001
   PubMed Web of Science ®Google Scholar
• Lee JS, Groebner JL, Hadjipanayis AG, Negley DL, Schmaljohn AL, Welkos SL, Smith LA, Smith JF. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 2006; 24:6886-92; PMID:16828936; http://dx.doi.org/10.1016/j.vaccine.2006.06.004
   PubMed Web of Science ®Google Scholar
• Aoki KR, Smith LA, Atassi MZ. Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition. Crit Rev Immunol 2010; 30:167-87; PMID:20370628; http://dx.doi.org/10.1615/CritRevImmunol.v30.i2.50
   PubMed Web of Science ®Google Scholar
• Atassi MZ. Molecular basis of immunogenicity to botulinum neurotoxins and uses of the defined antigenic regions. Toxicon 2015; 107(Pt A):50-58; http://dx.doi.org/10.1016/j.toxicon.2015.06.003
   PubMed Web of Science ®Google Scholar
• Karalewitz AP, Barbieri JT. Vaccines against botulism. Curr Opin Microbiol 2012; 15:317-24; PMID:22694934; http://dx.doi.org/10.1016/j.mib.2012.05.009
   PubMed Web of Science ®Google Scholar
• Potter KJ, Bevins MA, Vassilieva EV, Chiruvolu VR, Smith T, Smith LA, Meagher MM. Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris. Protein Expr Purif 1998; 13:357-65; PMID:9693060; http://dx.doi.org/10.1006/prep.1998.0910
   PubMed Web of Science ®Google Scholar
• Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, Smith LA. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 2007; 25:4273-82; PMID:17395341; http://dx.doi.org/10.1016/j.vaccine.2007.02.081
   PubMed Web of Science ®Google Scholar
• Dux MP, Barent R, Sinha J, Gouthro M, Swanson T, Barthuli A, Inan M, Ross JT, Smith LA, Smith TJ, et al. Purification and scale-up of a recombinant heavy chain fragment C of botulinum neurotoxin serotype E in Pichia pastoris GS115. Protein Expr Purif 2006; 45:359-67; PMID:16214371; http://dx.doi.org/10.1016/j.pep.2005.08.015
   PubMed Web of Science ®Google Scholar
• Johnson SK, Zhang W, Smith LA, Hywood-Potter KJ, Todd Swanson S, Schlegel VL, Meagher MM. Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastoris. Protein Expr Purif 2003; 32:1-9; PMID:14680933; http://dx.doi.org/10.1016/j.pep.2003.07.003
   PubMed Web of Science ®Google Scholar
• Zeng M, Xu Q, Elias M, Pichichero ME, Simpson LL, Smith LA. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 2007; 25:7540-8; PMID:17897756; http://dx.doi.org/10.1016/j.vaccine.2007.08.035
   PubMed Web of Science ®Google Scholar
• Atassi MZ, Oshima M. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol 1999; 19:219-60; PMID:10422600
   PubMed Web of Science ®Google Scholar
• Xu Q, Pichichero ME, Simpson LL, Elias M, Smith LA, Zeng M. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther 2009; 16:367-75; PMID:19129860; http://dx.doi.org/10.1038/gt.2008.181
   PubMed Web of Science ®Google Scholar
• Kumar A, Wonganan P, Sandoval MA, Li X, Zhu S, Cui Z. Microneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticles. J Control Release 2012; 163:230-9; PMID:22921518; http://dx.doi.org/10.1016/j.jconrel.2012.08.011
   PubMed Web of Science ®Google Scholar
• Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A 2000; 97:811-6; PMID:10639162; http://dx.doi.org/10.1073/pnas.97.2.811
   PubMed Web of Science ®Google Scholar
• Hoover DM, Lubkowski J. DNAWorks: an automated method for designing oligonucleotides for PCR-based gene synthesis. Nucleic Acids Res 2002; 30:e43; PMID:12000848; http://dx.doi.org/10.1093/nar/30.10.e43
   PubMed Web of Science ®Google Scholar
• Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 1999; 25:471-6; PMID:10194602; http://dx.doi.org/10.1081/DDC-100102197
   PubMed Web of Science ®Google Scholar
• Sloat BR, Sandoval MA, Cui Z. Towards preserving the immunogenicity of protein antigens carried by nanoparticles while avoiding the cold chain. Int J Pharm 2010; 393:197-202; PMID:20416366; http://dx.doi.org/10.1016/j.ijpharm.2010.04.003
   PubMed Web of Science ®Google Scholar
• Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011; 239:62-84; PMID:21198665; http://dx.doi.org/10.1111/j.1600-065X.2010.00980.x
   PubMed Web of Science ®Google Scholar
• Takahashi T, Joshi SG, Al-Saleem F, Ancharski D, Singh A, Nasser Z, Simpson LL. Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine 2009; 27:2616-24; PMID:19428868; http://dx.doi.org/10.1016/j.vaccine.2009.02.051
   PubMed Web of Science ®Google Scholar
• Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, et al. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun 2005; 73:5450-7; PMID:16113261; http://dx.doi.org/10.1128/IAI.73.9.5450-5457.2005
   PubMed Web of Science ®Google Scholar
• Fiock MA, Cardella MA, Gearinger NF. Studies on Immunity to Toxins of Clostridium Botulinum. Ix. Immunologic Response of Man to Purified Pentavalent Abcde Botulinum Toxiod. J Immunol 1963; 90:697-702; PMID:14054890
   PubMed Web of Science ®Google Scholar